{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:39:12Z","timestamp":1760402352281,"version":"build-2065373602"},"reference-count":17,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>A 79-year-old HIV-negative Caucasian man with a medical history of smoking 20 pack-years (quit 40 years prior), early-stage non-small cell lung cancer status post-lobectomy 13 years earlier at an outside hospital without evidence of recurrence, and benign prostatic hypertrophy was diagnosed with synchronous very high-risk prostate adenocarcinoma and early-stage anal basaloid squamous cell carcinoma. He proceeded to undergo concurrent treatment for these tumors, consisting of androgen deprivation therapy, external beam radiation therapy, and a brachytherapy boost for the prostate adenocarcinoma; for the anal carcinoma, he was treated with definitive chemoradiation. Over 3.5 years since the completion of radiotherapy, he remains in clinical and biochemical remission.<\/jats:p>","DOI":"10.3390\/curroncol29010033","type":"journal-article","created":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T20:44:00Z","timestamp":1642365840000},"page":"377-382","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnostic and Therapeutic Challenges in a Patient with Synchronous Very High-Risk Prostate Adenocarcinoma and Anal Carcinoma"],"prefix":"10.3390","volume":"29","author":[{"given":"Jonathan","family":"Wallach","sequence":"first","affiliation":[{"name":"Veterans Affairs New York Harbor Healthcare System, State University of New York-Downstate Medical Center, New York, NY 11209, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irini","family":"Youssef","sequence":"additional","affiliation":[{"name":"Veterans Affairs New York Harbor Healthcare System, State University of New York-Downstate Medical Center, New York, NY 11209, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Leaf","sequence":"additional","affiliation":[{"name":"Veterans Affairs New York Harbor Healthcare System, State University of New York-Downstate Medical Center, New York, NY 11209, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Veterans Affairs New York Harbor Healthcare System, State University of New York-Downstate Medical Center, New York, NY 11209, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"key":"ref_1","first-page":"864371","article-title":"Metachronous anal canal and prostate cancers with simultaneous definitive therapy: A case report and review of the literature","volume":"2011","author":"Miles","year":"2011","journal-title":"Case Rep. Oncol. Med."},{"key":"ref_2","unstructured":"National Comprehensive Cancer Network (2020, December 28). Anal Carcinoma (Version 2.2020). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/anal.pdf."},{"key":"ref_3","unstructured":"American Cancer Society (2020, December 28). Key Statistics for Anal Cancer. Available online: https:\/\/www.cancer.org\/cancer\/anal-cancer\/about\/what-is-key-statistics.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.soc.2016.07.001","article-title":"Epidemiology of Anal Canal Cancer","volume":"26","author":"Nelson","year":"2017","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_5","unstructured":"American Cancer Society (2020, December 28). Key Statistics for Prostate Cancer. Available online: https:\/\/www.cancer.org\/cancer\/prostate-cancer\/about\/key-statistics.html."},{"key":"ref_6","unstructured":"National Comprehensive Cancer Network (2020, December 28). Prostate Cancer (Version 3.2020). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","article-title":"Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer","volume":"98","author":"Morris","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.brachy.2016.05.001","article-title":"The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness","volume":"15","author":"Orio","year":"2016","journal-title":"Brachytherapy"},{"key":"ref_9","first-page":"6101759","article-title":"A Definitive IMRT-SIB with Concomitant Chemotherapy for Synchronous Locally Advanced Anal Canal Cancer and Prostate Cancer","volume":"2018","author":"Tubin","year":"2018","journal-title":"Case Rep. Oncol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: A Phase 2 Evaluation of Dose-Pained Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal Canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/pcan.2013.46","article-title":"Very-high-risk localized prostate cancer: Definition and outcomes","volume":"17","author":"Sundi","year":"2014","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.02.045","article-title":"Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial","volume":"104","author":"Pasalic","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e180039","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_14","unstructured":"Memorial Sloan Kettering Cancer Center (2020, December 29). Pre-Radical Prostatectomy. Prostate Cancer Nomograms. Available online: https:\/\/www.mskcc.org\/nomograms\/prostate\/pre_op."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N. Engl. J. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/1\/33\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:39:52Z","timestamp":1760362792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/1\/33"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["curroncol29010033"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29010033","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2022,1,15]]}}}